Repare Therapeutics has emerged from stealth mode with an impressive $68 million.
Vineti is launching its cloud-based system to streamline company processes and accelerate patient access to cell and gene therapies.
How PAREXEL's New Ecosystem of Technology, Processes and Expertise is Transforming Drug Development
Theranos and Walgreens have reached a tentative agreement to put the latter's breach-of-contract lawsuit to rest, WSJ sources say.
Sarepta Therapeutics has penned its second DMD gene therapy pact this year.
With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes.…
ImmunoCellular Therapeutics has suspended a phase 3 trial of its lead cancer vaccine after failing to raise the funds it needs to complete the study.
The FDA is working on a medical innovation development plan to lower healthcare costs by streamlining the path to market for targeted therapies.
Syntimmune has got off a beefy $50 million series B round.
Rubius Therapeutics has raised $120 million to take two of its off-the-shelf red blood cell therapies into the clinic.
German Merck and R&D charity CRUK are coming together to launch a biotech focused on immuno-oncology.
EvaluatePharma has totted up the figures for R&D spend and costs for biopharmas, and the figures are huge.